Spero Therapeutics (SPRO) Insider V.J.J. Buys 20,000 Shares
Vink Patrick V.J.J. purchased 10,000 shares of Spero Therapeutics on June 23, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Vink Patrick V.J.J. bought 20,000 shares of Spero Therapeutics, Inc. ($SPRO) on June 23, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SPRO is up 2.8% after 1 week, down 46.0% after 1 month and down 48.8% to date (from the $2.15 close on Jun 23, 2026).
SPRO
Spero Therapeutics, Inc.
Key Points
- Vink Patrick V.J.J. bought 10,000 shares of Spero Therapeutics, Inc. (SPRO) on June 23, 2026.
- Spero Therapeutics shares traded near $2.02 on Friday, with a market cap of approximately $116.96 million.
- Analyst firm HC Wainwright & Co. reiterated a buy rating with a $5.00 price target on January 30, 2025.
Get $SPRO trade alerts by text
We text you when insiders, Congress or big funds trade $SPRO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Spero Therapeutics, Inc. alert may contain errors. Disclosures
On June 23, 2026, Vink Patrick V.J.J. purchased 10,000 shares of Spero Therapeutics, Inc. (NasdaqGS: SPRO). This insider transaction did not involve a planned purchase, and no specific price or total value was disclosed. Shares traded near $2.02 on Friday.
Insider Buying and Selling at Spero Therapeutics, Inc.
Vink Patrick V.J.J. was not the only insider buying shares of Spero Therapeutics on June 23, 2026. Scott Thomas Jackson, John Jr. Pottage, Milind Deshpande, Cynthia Smith, and Frank Thomas each purchased 20,000 shares. These transactions were also not part of any pre-planned trading programs.
Spero Therapeutics, Inc. Stock Up 78.8%
Shares of NasdaqGS:SPRO traded near $2.02 on Friday. Spero Therapeutics, Inc. has a market cap of about $116.96 million, with a P/E ratio of 7.48. The stock's 52-week range is between $1.80 and $3.22, and it has a 50-day moving average of $2.63 and a 200-day moving average of $2.40. The company's beta is 1.456, indicating some volatility compared to the market.
Analysts Set New Price Targets
On January 30, 2025, HC Wainwright & Co. reiterated its buy rating for Spero Therapeutics with a price target of $5.00. The stock has a consensus recommendation of 'hold' based on one analyst opinion, with a mean target price of $4.00.
About Spero Therapeutics
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Cambridge, Massachusetts. It focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases. The company is advancing product candidates like Tebipenem HBr, an oral antibiotic targeting complicated urinary tract infections. Spero collaborates with Meiji Seika Pharma Co., Ltd. and Everest Medicines to develop and commercialize its treatments in various regions.
Bottom Line
Insider buying activity, like Vink Patrick V.J.J.'s purchase, often attracts attention from investors who track potential signals of confidence from company insiders. It's important to remember that these transactions are reported after they occur and may not reflect current positions. Spero Therapeutics continues to be a focus in the biotech sector, especially with its efforts in addressing multi-drug resistant infections.
Related Filing Alerts
Source: Vink Patrick V.J.J.'s Form 4 filing on $SPRO (Jun 23, 2026). Find the original filing: SPRO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts